Specific inhibition of microsomal Prostaglandin E synthesis, safety pharmacology advantage over NSAIDs?
|Coordinator||Gesynta Pharma AB|
|Funding from Vinnova||SEK 1 000 000|
|Project duration||June 2018 - May 2019|
|Venture||Swelife and Medtech4Health- Project proposals to improve health|
|Call||Förbättrad prevention, diagnos och behandling – Swelife och Medtech4health|
Purpose and goal
Gesynta Pharma AB, together with expertise from Swetox / RISE, investigated cardiovascular safety of the drug candidate GS-248. The microsomal Prostaglandin E synthase-1 inhibitor GS-248 had no adverse effect on cardiovascular function in a regulatory pharmacological animal model.
Expected results and effects
The result has provided a basis for continued funding up to, and including, Phase 1. In addition, the results have been included in an approved Phase 1 application to the Swedish Medical Products Agency. The Phase 1 study thus initiated will constitute the company´s main asset in the event of a possible out-licensing or sale.
Planned approach and implementation
A contract laboratory (LPT Laboratory of Pharmacology and Toxicology GmbH & Co.) conducted the cardiovascular safety study, which was evaluated by Swetox / RISE expertise. Analysis of samples, treatment of data from studies, as well as presentation of data for authorities, investors and potential partners has been performed by Gesynta, KI and RISE.